In a groundbreaking advancement poised to revolutionize the treatment of chronic diseases, researchers at Rice University, in collaboration with Carnegie Mellon and Northwestern Universities, have unveiled a pioneering implantable device designed to sustain living cell therapies within the human body. The device, known as the Hybrid Oxygenation Bioelectronics System for Implanted Therapy (HOBIT), overcomes a long-standing challenge in cell-based medicine: maintaining high cell densities alive and functional in subcutaneous implantation sites that traditionally suffer from poor oxygenation.
Cell therapies, which leverage genetically engineered living cells to act as miniature drug factories, hold immense potential to provide continuous, precise delivery of therapeutic proteins directly inside the body. However, the survival of these therapeutic cells depends critically on a reliable supply of oxygen and nutrients. Under the skin—a preferred location for minimally invasive implantation—oxygen availability is severely limited, forcing compromises between cell viability and therapeutic cell quantity. When cells are densely packed, they compete for scarce oxygen, leading to rapid cell death and loss of therapeutic efficacy.
Recognizing this bottleneck, the Rice-led team engineered HOBIT with a fully integrated, wireless oxygen-generation system that locally produces oxygen in situ. At the heart of the device lies a miniaturized electrocatalytic oxygenator featuring an iridium oxide-coated surface that uses electricity to split water molecules naturally present in surrounding tissues. This cutting-edge electrochemical process generates oxygen precisely where it is needed, sustaining densely packed cells without harmful byproducts. An onboard battery powers the oxygenator and can be wirelessly controlled and adjusted remotely to finely tune oxygen delivery based on therapeutic demand.
Distinct from prior oxygenation devices requiring external wiring, HOBIT’s compact, self-contained design compresses the oxygen producer, battery, electronics, and cell chamber into an assembly roughly the size of a folded stick of gum. This miniaturization not only facilitates implantation beneath the skin with minimal invasion and discomfort but also enables the device to be retrievable, allowing for future upgrades or removal. The device also shields therapeutic cells from immune attack using a sophisticated two-stage encapsulation scheme: cells are encapsulated within biocompatible alginate hydrogel microbeads, which are then housed within a semi-permeable membrane chamber. This configuration permits the unrestricted flow of nutrients, oxygen, and secreted biologics, while simultaneously protecting cells from host immune cells.
The therapeutic cells programmed inside HOBIT are extraordinary in their multifunctionality. They continuously manufacture and secrete three distinct biologic molecules that represent diverse therapeutic classes and exhibit different in vivo half-lives. These include an antibody to provide immune modulation, a hormone critical for metabolic balance, and exenatide—a GLP-1 receptor agonist analog used for glycemic control in diabetes. This multiplexed therapeutic secretion underscores HOBIT’s capacity to support complex treatment regimens through a single implant, a capability rarely achieved in existing cell-based therapies.
Collaborators emphasize that solving the oxygen supply problem is pivotal. “By producing oxygen directly inside the device, we effectively uncouple cell survival from the limitations of the host’s local tissue environment,” explained lead author Chris Wright, a Ph.D. student at Rice University. “We demonstrated that with HOBIT, we can sustain cell densities approximately sixfold greater than traditional encapsulation methods without oxygenation.” This represents a transformative leap in dosage potential, possibly enabling clinically meaningful therapeutic effects that were previously unattainable with subcutaneous implants.
Long-term animal studies confirmed the device’s superior performance. Rats implanted with oxygenated HOBIT devices maintained stable blood levels of the three secreted biologics for a full 30 days, whereas non-oxygenated control implants showed precipitous declines, particularly for short-lived molecule concentrations. Post-explant analysis revealed that about 65% of cells in oxygenated devices remained viable after one month, compared to only 20% in controls, illuminating the profound impact of localized oxygen generation on cellular survival and therapy durability.
The interdisciplinary research blend combining bioengineering, materials science, and electrochemistry was central to HOBIT’s success. Tzahi Cohen-Karni from Carnegie Mellon described it as a remarkable union of advanced materials design with biomedical innovation. Northwestern’s Jonathan Rivnay highlighted the system’s ability to be wirelessly modulated and remotely programmed, opening the door for dynamic, patient-specific treatment adaptation without repeated surgeries or interventions.
This versatile platform does not only promise new avenues for diabetes—an area of keen interest given pancreatic islets’ notoriously high oxygen demand—but also sets the stage for treating myriad chronic conditions requiring sustained protein biologic delivery. The researchers envision future iterations integrating multiple cell types, biosensors, and controlled secretion systems within retrievable implants, crafting a sophisticated therapeutic technology akin to a personalized, artificial endocrine organ.
Looking ahead, the team plans to scale testing to larger animal models and refine disease-specific implementations to validate clinical translatability. The ultimate objective is to overcome the intrinsic limitations of traditional drug administration—frequent dosing, off-target effects, and variable pharmacokinetics—by embedding living, programmable cell factories directly into patients, thereby providing continuous, controlled, and multimodal therapeutic interventions.
While the HOBIT platform currently focuses on oxygenation to sustain encapsulated cells, its broader implications resonate through bioelectronic medicine and implantable device landscapes. By marrying metabolic support with immune protection and wireless functionality, this innovation could catalyze a paradigm shift, ushering in an era where once laborsome therapeutic regimens are replaced by implantable, sustainable, and smart bio-factories inside the human body.
The research, recently published in the journal Device, was supported by multiple funding bodies including Breakthrough T1D and the U.S. Defense Advanced Research Projects Agency. The inventors have filed a provisional patent application and are commercializing the technology through DuraCyte, a startup company co-founded by several lead researchers, signaling an active pathway toward clinical development and commercialization.
In sum, HOBIT exemplifies how convergence between engineering disciplines and biological sciences can solve intricate physiological challenges, bringing forth transformative solutions that offer hope for more effective, less burdensome treatments for patients worldwide. This hybrid bioelectronic platform fosters a future where “smart” implants may one day replace conventional pharmaceuticals, establishing a new frontier in personalized medicine.
Subject of Research:
Implantable cell therapies with integrated oxygenation for enhanced cell viability and therapeutic efficacy
Article Title:
Design of a wireless, fully implantable platform for in-situ oxygenation of encapsulated cell therapies
News Publication Date:
March 27, 2026
Web References:
https://doi.org/10.1016/j.device.2026.101106
https://news.rice.edu
References:
Wright, C., Surendran, A., Lee, I., Villacres, J., Ezerins, A., Curtiss, A., Brown, N., Liu, J., Rothrock, B., Wang, H., Fell, C., Davis, A., Hester, J., Cohen-Karni, T., Rivnay, J., Veiseh, O. (2026). Design of a wireless, fully implantable platform for in-situ oxygenation of encapsulated cell therapies. Device. https://doi.org/10.1016/j.device.2026.101106
Image Credits:
Photo by Jared Jones, Rice University
